Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer.

Front Oncol · 2026 · PMC13423639 · PMID 42539411

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

After a median follow-up of 15.6 months, the efficacy data across the three cohorts clearly demonstrated an increasing trend in benefit corresponding with higher HER2 expression levels.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.